Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc. (ANEB) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ANEB · as of Sep 30, 2025
Ownership Breakdown
20
Institutional Holders
▲ 2 vs Q2
$55.55M
Total Inst. Value
▲ $23.02M vs Q2
40.78M
Shares Outstanding
freeFloat 59.16%
22.22M
13F Shares Held
▼ 372,183 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ANEB largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
22NW, LP pharmaceutical preparations | 15.47M | 45.73% | 45.73% | $38.67B | Nov 14, 2025 | — held |
NANTAHALA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.04M | 8.98% | 8.98% | $7.59B | Nov 14, 2025 | — held |
MANGROVE PARTNERS pharmaceutical preparations | 2.53M | 7.47% | 7.47% | $6.31B | Nov 14, 2025 | — held |
MORGAN STANLEY pharmaceutical preparations | 399.4K | 1.18% | 1.18% | $998.51M | May 27, 2026 | ▲ 185 |
VANGUARD GROUP INC pharmaceutical preparations | 306.5K | 90.64% | 90.64% | $766.35M | Nov 7, 2025 | ▲ 90.6K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 174.1K | 51.48% | 51.48% | $435.57M | Nov 12, 2025 | ▼ 31.6K |
IKARIAN CAPITAL, LLC pharmaceutical preparations | 157.7K | 46.63% | 46.63% | $394.30M | Nov 14, 2025 | — held |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 28.5K | 8.43% | 8.43% | $71.25M | Nov 13, 2025 | NEW |
NORTHERN TRUST CORP pharmaceutical preparations | 24.4K | 7.21% | 7.21% | $60.98M | Nov 14, 2025 | NEW |
BLACKROCK, INC. pharmaceutical preparations | 24.1K | 7.11% | 7.11% | $60.15M | Nov 12, 2025 | ▲ 6.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
5
Increased
+99.9K shares7
New Positions
first time holders3
Decreased
−35.7K shares6
Sold Out
fully exitedNet shares change (top 50)
+64.2K
+99.9K / −35.7K
Net new holders
+3
7 new / 6 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ANEB insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lawler Joseph F.
| Apr 4, 2025 | Award | 25,000 | $1.02 | $25.5K | 25.0K | Form 4 ↗ |
Lawler Joseph F.
| Apr 4, 2025 | Award | 13,236 | $1.02 | $13.5K | 13.2K | Form 4 ↗ |
SHAH BIMAL R. director | Apr 4, 2025 | Award | 25,000 | $1.02 | $25.5K | 25.0K | Form 4 ↗ |
SHAH BIMAL R. director | Apr 4, 2025 | Award | 6,618 | $1.02 | $6.8K | 6.6K | Form 4 ↗ |
Cundy Kenneth C Chief Scientific Officer | Apr 4, 2025 | Award | 115,037 | $1.02 | $117.3K | 115.0K | Form 4 ↗ |
Aryeh Jason director | Apr 4, 2025 | Award | 25,000 | $1.02 | $25.5K | 25.0K | Form 4 ↗ |
Aryeh Jason director | Apr 4, 2025 | Award | 4,964 | $1.02 | $5.1K | 5.0K | Form 4 ↗ |
Cunningham, Richard Anthony Chief Executive Officer | Apr 4, 2025 | Award | 316,352 | $1.02 | $322.7K | 316.4K | Form 4 ↗ |
Lin Kenneth director | Apr 4, 2025 | Award | 25,000 | $1.02 | $25.5K | 25.0K | Form 4 ↗ |
Lin Kenneth director | Apr 4, 2025 | Award | 4,964 | $1.02 | $5.1K | 5.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Anebulo Pharmaceuticals, Inc. (ANEB) is primarily owned by institutional investors, who hold approximately 54.5% of total shares outstanding. Company insiders own approximately 40.84%, while retail and public investors account for the remaining 4.68%.
The largest institutional shareholder of Anebulo Pharmaceuticals, Inc. is 22NW, LP, holding approximately 15.47 million shares — equal to 45.73% of outstanding shares — as of September 30, 2025.
A total of 20 institutional investors currently hold ANEB stock, with a combined institutional value of approximately $55,549,711 as of the most recent 13F filing period.
Frequently asked questions
ANEB ownershipAnebulo Pharmaceuticals, Inc. (ANEB) is primarily owned by institutional investors, who hold approximately 54.5% of shares. The largest shareholder is 22NW, LP with a 45.73% stake. Company insiders hold 40.84%. Data sourced from SEC Form 13F as of September 30, 2025.